BNY Mellon Reports $608.5B in 13F Equity Holdings for Q3 2026

Executive Summary

On November 5, 2026, Bank of New York Mellon Corp filed its Form 13F-HR quarterly holdings report for the period ending September 30, 2026. As an institutional investment manager, BNY Mellon disclosed a total portfolio value of $608,486,273,647 distributed across 34,105 reported entries.

Filing Overview

• Filer: Bank of New York Mellon Corp
• Form Type: 13F-HR (13F Combination Report)
• Period of Report: September 30, 2026
• SEC File Number: 028-12592
• Other Included Managers Count: 15 sub-managers and investment advisers, including Mellon Investments Corporation, BNY Mellon Investment Adviser, Inc., Newton Investment Management Limited, and The Bank of New York Mellon.

Portfolio Highlights from Sampled Entries

The filing details substantial positions across large-cap healthcare, industrials, and technology, including:

• AbbVie Inc (ABBV): Multi-billion-dollar aggregate exposure across multiple entities, including over 6.3M shares through manager 15 and 3.3M shares through manager 48.
• Abbott Laboratories (ABT): Core multi-million-share position exceeding $800M across primary BNY Mellon advisory and custodial branches.
• 3M Co (MMM): Major stake including over 1.4M shares under manager 15 and nearly 1M shares under manager 48.

Trading Significance

Form 13F filings are backward-looking reports reflecting institutional holdings as of quarter-end rather than insider transactions. As such, the direct trading significance is rated Low, though the data serves as a key benchmark for institutional ownership trends.